Precision Oncology and the Evolution of Breast Cancer Care

被引：0

作者：

Guinigundo, Andrew S. ^{[1
]}

机构：

[1] Cincinnati Canc Advisors, Precis Oncol, Cincinnati, OH 45212 USA

来源：

CLINICAL JOURNAL OF ONCOLOGY NURSING | 2025年 / 29卷 / 03期

关键词：

breast cancer; precision oncology; germline genetic testing; targeted therapy; BENEFIT; PREDICTION; TAMOXIFEN; THERAPY; INDEX;

D O I：

10.1188/25.CJON.196-200

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinicians have practiced precision oncology in breast cancer care for decades. Genetic and genomic testing technology has allowed for personalized cancer risk assessment, prognosis determination, and treatment of the disease. Oncology nurses and nurse practitioners familiar with the various aspects of precision oncology can provide education and supportive care, order testing, and act on test results in accordance with their scope of practice.

引用

页码：196 / 200

页数：5

共 27 条

[1]

American Society of Breast Surgeons, 2019, Clinical consensus statement: Genetic testing for hereditary breast cancer

[2]

AstraZeneca, 2023, BEGO VarseoSmile® Crown Plus-Scientific Studies

[3]

AstraZeneca, 2023, Lynparza® (olaparib)

[4] Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer [J].

Bardia, Aditya ;

Hu, X. ;

Dent, Rebecca ;

Yonemori, Kan ;

Barrios, Carlos H. ;

O'Shaughnessy, Joyce A. ;

Wildiers, Hans ;

Pierga, Jean-Yves ;

Zhang, Qingyuan ;

Saura, Cristina ;

Biganzoli, Laura ;

Sohn, Joohyuk ;

Im, Seock-Ah ;

Levy, Christelle ;

Jacot, William ;

Begbie, Natasha ;

Ke, Jun ;

Patel, Gargi ;

Curigliano, Giuseppe .

NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (22) :2110-2122

[5] Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial [J].

Bartlett, J. M. S. ;

Sgroi, D. C. ;

Treuner, K. ;

Zhang, Y. ;

Ahmed, I ;

Piper, T. ;

Salunga, R. ;

Brachtel, E. F. ;

Pirrie, S. J. ;

Schnabel, C. A. ;

Rea, D. W. .

ANNALS OF ONCOLOGY, 2019, 30 (11) :1776-1783

[6] Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial [J].

Bidard, Francois-Clement ;

Kaklamani, Virginia G. ;

Neven, Patrick ;

Streich, Guillermo ;

Montero, Alberto J. ;

Forget, Frederic ;

Mouret-Reynier, Marie-Ange ;

Sohn, Joo Hyuk ;

Taylor, Donatienne ;

Harnden, Kathleen K. ;

Khong, Hung ;

Kocsis, Judit ;

Dalenc, Florence ;

Dillon, Patrick M. ;

Babu, Sunil ;

Waters, Simon ;

Deleu, Ines ;

Saenz, Jose A. Garcia ;

Bria, Emilio ;

Cazzaniga, Marina ;

Lu, Janice ;

Aftimos, Philippe ;

Cortes, Javier ;

Liu, Shubin ;

Tonini, Giulia ;

Laurent, Dirk ;

Habboubi, Nassir ;

Conlan, Maureen G. ;

Bardia, Aditya .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) :3246-+

[7] ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer [J].

Brett, Jamie O. ;

Spring, Laura M. ;

Bardia, Aditya ;

Wander, Seth A. .

BREAST CANCER RESEARCH, 2021, 23 (01)

[8]

Brophy L., ONS Biomarker Database: Breast cancer

[9]

Genetech, 2024, ItovebiTM (inavolisib)

[10] Specificity of HercepTest in determining HER-2/neu status of breast cancers using the united states food and drug administration-approved scoring system [J].

Jacobs, TW ;

Gown, AM ;

Yaziji, H ;

Barnes, MJ ;

Schnitt, SJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :1983-1987

← 1 2 3 →